Craft

Kringle Pharma

Revenue

¥72.2 M

FY, 2025

Kringle Pharma Summary

Company Summary

Overview
Kringle Pharma is a clinical-stage biopharmaceutical company that focuses on the research and development of regenerative medicines. It offers protein drug substance products for the treatment of vocal cord scarring, acute kidney and spinal cord injury, amyotrophic lateral sclerosis, cancer patients, etc.
Type
Public
Status
Active
Founded
2001
HQ
Ibaraki, JP | view all locations
Website
https://www.kringle-pharma.com
Cybersecurity rating
Sectors

Key People

  • Kiichi Adachi

    Kiichi Adachi, President, CEO and Director

  • Koichi Murakami

    Koichi Murakami, Director

    • Hayata Daishin

      Hayata Daishin, Director

      • Yoshiyuki Kayano

        Yoshiyuki Kayano, Director

        LocationsView all

        1 location detected

        • Ibaraki, Osaka HQ

          Japan

          207 Saito Bio Incubator, 7-7-15 Saitoasagi

        Kringle Pharma Financials

        Summary Financials

        Revenue (Q2, 2026)
        ¥18.2M
        Gross profit (Q2, 2026)
        ¥18.2M
        Net income (Q2, 2026)
        (¥314.7M)
        Cash (Q1, 2026)
        ¥1.5B
        EBIT (Q2, 2026)
        (¥315.2M)

        Footer menu